Search
Showing results for "Au"
Research
Twenty years of surveillance in Rett syndrome: what does this tell us?This study aimed to describe overall survival and adult health in those with Rett syndrome.
Research
Morbidity in survivors of child and adolescent meningiomaGiven the paucity of data concerning long-term outcome, the authors undertook a meta-analysis to analyze morbidity in survivors of this disease.
Research
Changes in risk factors for preterm birth in Western Australia 1984-2006Marked increases in maternal age and primiparous births were observed. A four-fold increase in the rates of pre-existing medical complications over time...
Research
Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.
Research
Access to Oral Healthcare in Individuals With Rett Syndrome: A Qualitative Study of Parent PerspectivesIntellectual and developmental disabilities (IDD) are varied in their nature and presentation. Barriers to oral healthcare are reported in studies of general populations with IDD but these may not reflect the barriers experienced by individuals with rare disorders such as Rett syndrome.
News & Events
Clinical trial recruiting babies for RSV and hMPV vaccine studyMEDIA ENQUIRIES Discover. Prevent. Cure. Mailing list Media contacts About The Kids Be Inspired Please direct general enquiries to our reception on (
Contact us If you'd like to get in touch, please contact us by phone or email. Phone: 0400 450 240 Email: vtg@thekids.org.au Respiratory Syncytial
Research
Lessons from the first year of the WAIVE study investigating the protective effect of influenza vaccineInfluenza is major cause of paediatric hospitalisation. Influenza vaccine was offered to all children aged 6-59 months resident in Western Australia in 2008
Research
The -2518bp promoter polymorphism at CCL2/MCP1 influences susceptibility to mucosal but not localizedMucosal leishmaniasis (ML) follows localized cutaneous leishmaniasis (CL) caused by Leishmania braziliensis.
Research
Updating the profile of C-terminal MECP2 deletions in Rett syndromeThis study aimed to compare the phenotype of Rett syndrome cases with C-terminal deletions to that of cases with different MECP2 mutations